KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) Consolidated Net Income: 2010-2025

Historic Consolidated Net Income for Rigel Pharmaceuticals (RIGL) over the last 14 years, with Sep 2025 value amounting to $27.9 million.

  • Rigel Pharmaceuticals' Consolidated Net Income rose 124.62% to $27.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $113.2 million, marking a year-over-year increase of 2817.96%. This contributed to the annual value of $17.5 million for FY2024, which is 169.61% up from last year.
  • Latest data reveals that Rigel Pharmaceuticals reported Consolidated Net Income of $27.9 million as of Q3 2025, which was down 53.20% from $59.6 million recorded in Q2 2025.
  • Rigel Pharmaceuticals' 5-year Consolidated Net Income high stood at $59.6 million for Q2 2025, and its period low was -$27.4 million during Q1 2022.
  • Its 3-year average for Consolidated Net Income is $8.3 million, with a median of $737,000 in 2023.
  • Per our database at Business Quant, Rigel Pharmaceuticals' Consolidated Net Income slumped by 169.53% in 2022 and then spiked by 5,887.67% in 2025.
  • Over the past 5 years, Rigel Pharmaceuticals' Consolidated Net Income (Quarterly) stood at -$22.6 million in 2021, then soared by 106.20% to $1.4 million in 2022, then slumped by 47.39% to $737,000 in 2023, then spiked by 1,843.28% to $14.3 million in 2024, then surged by 124.62% to $27.9 million in 2025.
  • Its Consolidated Net Income was $27.9 million in Q3 2025, compared to $59.6 million in Q2 2025 and $11.4 million in Q1 2025.